Cover Image
市場調查報告書

肝血管瘤:全球臨床實驗動向

Hemangiomas Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 296488
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
肝血管瘤:全球臨床實驗動向 Hemangiomas Global Clinical Trials Review, H2, 2017
出版日期: 2017年09月01日 內容資訊: 英文 79 Pages
簡介

本報告提供全球肝血管瘤治療藥臨床實驗相關調查,提供各地區的臨床實驗數資料,實驗階段,實驗狀況及各類型贊助企業的臨床實驗資料,為您概述為以下內容。

目錄

簡介

  • 肝血管瘤
  • 報告指南

臨床實驗: 各地區

  • 臨床實驗及被實驗人數: 各國
    • 亞太地區:前五名國家
    • 歐洲:前五名國家
    • 北美:前幾名國家
    • 中東·非洲:前幾名國家
    • 中南美:前幾名國家

臨床實驗 G7各國

臨床實驗 G7各國:各臨床實驗狀態

臨床實驗 E7各國

臨床實驗 E7各國:各臨床實驗狀態

各階段臨床實驗:

  • 進行中的臨床實驗:各階段

各臨床實驗狀態臨床實驗:

一定期間內募集的實驗對象

贊助商各類型臨床實驗

有力的贊助商

  • 主要的參與臨床實驗企業

潛力治療藥物

臨床實驗簡介

  • 臨床實驗概要: 主要企業
    • Laboratoires Pierre Fabre SA
    • MethylGene Inc
    • Maruho Co., Ltd
    • InfectoPharm Arzneimittel und Consilium GmbH
  • 臨床實驗概要: 主要大學 / 研究機關 / 醫院
    • Medical College of Wisconsin
    • The University of New Mexico
    • The Hospital for Sick Children
    • 慶應大學
    • The Ohio State University
    • Southwest Hospital, China
    • Oregon Health and Science University
    • National Institute of Neurological Disorders and Stroke
    • Eastern Hepatobiliary Surgery Hospital
    • National Cancer Institute

5個主要的臨床實驗簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4549CTIDB

GlobalData's clinical trial report, "Hemangiomas Global Clinical Trials Review, H2, 2017" provides an overview of Hemangiomas clinical trials scenario. This report provides top line data relating to the clinical trials on Hemangiomas. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 3
  • Report Guidance 4
  • GlobalData Clinical Trials Report Coverage 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Hemangiomas to Non Malignant Disorders Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Hemangiomas to Non Malignant Disorders Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials in E7 Countries by Trial Status 19
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in Hemangiomas Therapeutics Clinical Trials 28
  • Prominent Drugs 30
  • Clinical Trial Profile Snapshots 31

Appendix 77

  • Abbreviations 77
  • Definitions 77
  • Research Methodology 78
  • Secondary Research 78
  • About GlobalData 79
  • Contact Us 79
  • Source 79

List of Tables

List of Tables

  • Hemangiomas Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Hemangiomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Hemangiomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Hemangiomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 9
  • Hemangiomas Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
  • Hemangiomas Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
  • Hemangiomas Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 12
  • Hemangiomas Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 13
  • Proportion of Hemangiomas to Non Malignant Disorders Clinical Trials, G7 Countries (%), 2017* 14
  • Hemangiomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Hemangiomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Proportion of Hemangiomas to Non Malignant Disorders Clinical Trials, E7 Countries (%), 2017* 17
  • Hemangiomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
  • Hemangiomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Hemangiomas Therapeutics, Global, Clinical Trials by Phase, 2017* 20
  • Hemangiomas Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 21
  • Hemangiomas Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
  • Hemangiomas Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
  • Hemangiomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
  • Hemangiomas Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 25
  • Hemangiomas Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Hemangiomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Hemangiomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures

List of Figures

  • Hemangiomas Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
  • Hemangiomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Hemangiomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Hemangiomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 9
  • Hemangiomas Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 10
  • Hemangiomas Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 11
  • Hemangiomas Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 12
  • Hemangiomas Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 13
  • Proportion of Hemangiomas to Non Malignant Disorders Clinical Trials, G7 Countries (%), 2017* 14
  • Hemangiomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Hemangiomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Proportion of Hemangiomas to Non Malignant Disorders Clinical Trials, E7 Countries (%), 2017* 17
  • Hemangiomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
  • Hemangiomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Hemangiomas Therapeutics, Global, Clinical Trials by Phase (%), 2017* 20
  • Hemangiomas Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 21
  • Hemangiomas Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
  • Hemangiomas Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
  • Hemangiomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
  • Hemangiomas Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 25
  • Hemangiomas Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 26
  • Hemangiomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Hemangiomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
  • GlobalData Methodology 78
Back to Top